Funding for this research was provided by:
Fujian Provincial Platform for Medical Laboratory Research and Key Laboratory for Tumor Individualized Active Immunity (FYKFKT-2017015)
Text and Data Mining valid from 2019-07-22
Received: 3 May 2019
Accepted: 15 July 2019
First Online: 22 July 2019
Ethics approval and consent to participate
: This retrospective study was approved by Fujian Province Cancer Hospital Institutional Review Board (NO. KT2018–014-01). All patients provided written informed consent prior to treatment, and all information was anonymized prior to analysis.
: Not applicable.
: The authors declare the submitted work was not carried out in the presence of any personal, professional or financial relationships that could potentially be construed as a conflict of interest.